- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04358913
MR Imaging Study Using the Northern Alberta Linac-MR (Northern LIGHTs - 1)
January 29, 2024 updated by: AHS Cancer Control Alberta
Northern Alberta Linac-MR Image-Guided Human Clinical Trials - 1
Cancers are often treated with external beam radiotherapy.
Current radiotherapy treatments are performed using computed tomography (also known as CT) scans which may not always clearly identify the cancer.
In some instances, magnetic resonance imaging (MRI) may be able to better identify cancers.
Therefore, efforts are currently underway to use the MRI scans to improve radiotherapy treatments or eventually even use radiotherapy equipment that only uses MRI scans to guide treatments.
This new technology that will only use MRI scans to guide treatments is called the Linac-MR (linear accelerator with an MRI).
The purpose of this pilot phase of the study is to test whether the Alberta linac-MR P3 system at the Cross Cancer Institute can acquire high quality MR images safely.
It will allow the researchers to develop the best collection of MR images possible with this new machine, in order to allow them to visualize tumors for future patients that are treated on this machine.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This prospective, pilot phase, clinical trial is an imaging study to optimize the necessary MR sequences on the Alberta linac-MR P3 system to allow for MR-guided radiotherapy in adult patients with cancer that are treated with high dose external beam radiotherapy.
Each participant will undergo a single MR imaging session (30 - 40 minutes) on the Alberta linac-MR P3 system.
Towards the end of the study, patients will be approached to participate in an optional sub-study, where they will undergo a total of five MR imaging sessions (performed every two to five days) to allow for an assessment of inter-fraction motion.
Study Type
Interventional
Enrollment (Estimated)
100
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Nawaid Usmani, MD
- Phone Number: 780-432-8518
- Email: Nawaid.Usmani@ahs.ca
Study Locations
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 1Z2
- Recruiting
- Cross Cancer Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Adults ≥ 18 years of age
- Patients deemed fit to undergo high dose external beam radiation therapy by their attending radiation oncologist
Exclusion Criteria:
- Patients with contraindications for MRI
- Patients who are unable to lie flat and still for the duration of the expected scan acquisition
- Patients who are unable to provide informed consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Device Feasibility
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MR Imaging on the Alberta linac-MR P3 system
All participants will undergo a single MR imaging session (30-40 minutes) on the Alberta linac-MR P3 system.
|
Single MR imaging session to develop and optimize the necessary MR sequences on the Alberta linac-MR P3 system to allow for MR-guided radiotherapy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of high-quality MR image data sets acquired for each major tumour site (prostate, liver, lung, CNS, and breast)
Time Frame: Through study completion, approximately 1 year
|
Clinical radiologists, medical physicists, and radiation oncologists will work together to develop MR sequences that can delineate tumour target volumes on the Alberta linac-MR P3 system.
Over the course of the trial, the clinical radiologists will work with medical physicists to optimize these sequences to allow for the development of optimal MR images, with the goal to develop of series of protocols that can be utilized to provide clear MR image guidance for each tumour group.
|
Through study completion, approximately 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quantify the patient experience on the Linac-MR
Time Frame: After the first and last scan, up to 5 weeks
|
Participants will complete a questionnaire at the end of their first scan regarding their experience having imaging done on the Linac-MR.
Participants taking part in the optional sub-study will complete the same questionnaire at the end of their last set of imaging.
|
After the first and last scan, up to 5 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Nawaid Usmani, MD, Cross Cancer Institute, Alberta Health Services
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 23, 2021
Primary Completion (Estimated)
December 1, 2024
Study Completion (Estimated)
December 1, 2024
Study Registration Dates
First Submitted
April 9, 2020
First Submitted That Met QC Criteria
April 21, 2020
First Posted (Actual)
April 24, 2020
Study Record Updates
Last Update Posted (Actual)
January 30, 2024
Last Update Submitted That Met QC Criteria
January 29, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Other Study ID Numbers
- IIT-0013
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
Case Comprehensive Cancer CenterCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer and other conditionsUnited States
Clinical Trials on MR scan with the Alberta linac-MR P3 system
-
AHS Cancer Control AlbertaRecruiting
-
University Hospital TuebingenRecruitingBreast Cancer | Head and Neck Cancer | Esophageal Cancer | Rectal Cancer | Prostate Cancer | Liver Cancer | OligometastasisGermany
-
Sunnybrook Health Sciences CentreNot yet recruitingHead and Neck Cancer
-
Washington University School of MedicineCompletedOligometastases of the SpineUnited States
-
University of ZurichRecruitingGlioblastoma MultiformeSwitzerland
-
Royal Marsden NHS Foundation TrustRecruitingProstate AdenocarcinomaUnited Kingdom
-
Dana-Farber Cancer InstituteSuspendedLung Cancer | Prostate Cancer | Mesothelioma | Liver Metastases | Pancreas Cancer | Renal Cancer | Brain Metastases | Spine Metastases | Borderline Resectable Pancreatic Carcinoma | Adrenal Metastases | Oligoprogressive Nodal Metastases | Metachronous Nodal Metastases | Synchronous Nodal MetastasesUnited States
-
Dr. Marjon H. Cnossen MD PhDAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)RecruitingSickle Cell Disease | Brain Development AbnormalityNetherlands
-
Abbott Medical DevicesCompletedParkinson Disease | Movement Disorders | Dystonia | Essential Tremor | TremorUnited States, Spain, Germany, France, Sweden
-
University of Maryland, BaltimoreInSightec; Focused Ultrasound FoundationNot yet recruitingTask-Specific Focal DystoniaUnited States